Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Inclusion Criteria: Subject must be able to provide informed consent Subject must be 18 years of age or older Subject must have histologically confirmed ACC by Department of Pathology at Dartmouth Hitchcock Medical Center Subject must have inoperable disease Subject must have received some form of systemic therapy prior to enrolling in the study Exclusion Criteria: known severe hypersensitivity to Iressa other co-existing malignancies diagnosed within the last five years except basal cell cancer or cervical cancer in situ any unresolved CTC grade 2 toxicity from previous anticancer therapy (except alopecia) absolute neutrophil count less than 1.5 x 1,000,000,000 per liter platelets less than 20 x 1,000,000,000 per liter severe uncontrolled systemic disease pregnancy\breastfeeding women who are fertile and not willing to practice abstinence or contraception use of phenytoin, carbamazepine, rifampicin, barbiturates, or St. John's Wort treatment with a non-approved or investigational drug within 28 days before Day 1 of study treatment prior use of ZD1839 (Iressa) or any other anti-EGFR therapies